CSL (CSLLY) 5-Year EBITDA Growth Rate: 10.80% (As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $21.03
GF Value $50.62
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL 5-Year EBITDA Growth Rate?

CSL CSLLY -2.68% 73 5-Year EBITDA Growth Rate is 10.80% as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.62 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL's EBITDA per Share for the six months ended in Dec. 2025 was $0.54.

During the past 12 months, CSL's average EBITDA Per Share Growth Rate was -77.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 15.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 10.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CSL was 64.60% per year. The lowest was -1.40% per year. And the median was 14.80% per year.

CSL  (OTCPK:CSLLY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

CSL 5-Year EBITDA Growth Rate Related Terms

CSLLY vs VRTX, REGN, ALNY: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, CSL's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CSL's 5-Year EBITDA Growth Rate falls into.


CSLLY
73GF Score
CSL Ltd CSLLY
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 10.80% mean?
CSL (CSLLY) has a 5-Year EBITDA Growth Rate of 10.80% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for CSL and its competitors.
Is CSL's 5-Year EBITDA Growth Rate too high?
CSL's current 5-Year EBITDA Growth Rate is 10.80%. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
CSL's 5-Year EBITDA Growth Rate of 10.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for CSL and its competitors. CSL's current 5-Year EBITDA Growth Rate is 10.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.62, compared to a current price of $21.03 — trading 58.5% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 10.80%. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current 5-Year EBITDA Growth Rate is 10.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $21.03 is trading 58.5% below its estimated GF Value™ of $50.62. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • 5-Year EBITDA Growth Rate: 10.80%
  • GF Value™: $50.62 vs. price of $21.03 (58.5% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.03
Price
$50.62
GF Value